Sequentify develops ultra-fast InfiniSeq targeted DNA sequencing technology for diagnostics and surveillance. The company was awarded a grant by the Israel Innovation Authority that contributes to a project totaling $1.3 million to support development of a targeted sequencing panel for infectious disease research. The panel aims to provide a culture-free, next-day solution for sequencing pathogens, with a focus on pathogen diagnosis and antibiotic resistance surveillance. The grant is intended to advance R&D and enhance the utility of InfiniSeq in infectious-disease applications, aligning with Sequentify's broader commercial goals. Sequentify leverages tools from synthetic biology and AI software for targeted sequencing applications including cancer diagnostics, carrier screening, and COVID-19 surveillance. The company was founded in 2021 as a Weizmann Institute of Science spinoff and is based in Rehovot, Israel. Sequentify develops InfiniSeq, a proprietary platform that combines synthetic biology tools and AI software to enable rapid, targeted DNA sequencing and library preparation for NGS. Its InfiniSeq workflow reduces sample-preparation time to about 3.5 hours with a one-tube reaction, full automation support, and compatibility with most sequencing instruments. The company's products target applications including COVID-19 surveillance, cancer diagnostics, and carrier screening, and it is expanding support for liquid biopsy, epigenomics, and virology. Sequentify reports being on track to 600% revenue growth, already counts multiple hospitals and labs as customers, and has seen over 70x valuation growth in less than 18 months. Founded in 2021 as a Weizmann Institute of Science spinoff and based in Rehovot, Israel, the company aims to decentralize NGS into local labs and hospitals. Proceeds from its recent fundraise will be used to accelerate R&D, delivery, and go-to-market plans to make genomics more accessible and affordable.

Total raised

$8M

Funding rounds

2

Latest round

Grant

Latest activity

Jan 2024